Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In Brief Objective: We present and analyze long-term outcomes following multimodal therapy for esophageal cancer, in particular the relative impact of histomorphologic tumor regression and nodal status. Patients and Methods: A total of 243 patients [(adenocarcinoma (n = 170) and squamous cell carcinoma (n = 73)] treated with neoadjuvant chemoradiotherapy in the period 1990 to 2004 were followed prospectively with a median follow-up of 60 months. Pathologic stage and tumor regression grade (TRG) were documented, the site of first failure was recorded, and Kaplan-Meier survival curves were plotted. Results: Thirty patients (12%) did not undergo surgery due to disease progression or deteriorated performance status. Forty-one patients (19%) had a complete pathologic response (pCR), and there were 31(15%) stage I, 69 (32%) stage II, and 72 (34%) stage III cases. The overall median survival was 18 months, and the 5-year survival was 27%. The 5-year survival of patients achieving a pCR was 50% compared with 37% in non-pCR patients who were node-negative (P = 0.86). Histomorphologic tumor regression was not associated with pre-CRT cTN stage but was significantly (P < 0.05) associated with ypN stage. By multivariate analysis, ypN status (P = 0.002) was more predictive of overall survival than TRG (P = 0.06) or ypT stage (P = 0.39). Conclusion: Achieving a node-negative status is the major determinant of outcome following neoadjuvant chemoradiotherapy. Histomorphologic tumor regression is less predictive of outcome than pathologic nodal status (ypN), and the need to include a primary site regression score in a new staging classification is unclear. A prospective analysis of 243 patients with localized esophageal cancer treated with neoadjuvant chemoradiation followed by surgery was undertaken, and long-term outcomes reported. Pathologic node-negative status (ypN0) was the most powerful (P = 0.002) determinant of survival. Neither histomorphologic tumor regression (TRG; P = 0.06) nor depth of invasion (ypT; P = 0.39) was significantly associated with survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., Estes, N., Haller, D. G., Ajani, J., Kocha, W., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392704 · Cited by 1,343
Cited by
Ryan, A. M., Reynolds, J. V., Healy, L., Byrne, M., Moore, J., Brannelly, N., McHugh, A., McCormack, D., & Flood, P. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e31819a4789 · Cited by 311
Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015) · Oncology · doi:10.1159/000381065 · Cited by 36
Metadata
- Authors
- Reynolds, J. V., Muldoon, C., Hollywood, D., Ravi, N., Rowley, S., O’Byrne, K., Kennedy, J., & Murphy, T. J.
- Venue
- Annals of Surgery
- Published
- 2007-05
- Volume
- 245
- Issue
- 5
- Pages
- 707-716
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2083168580
- Cited by
- 161
- References
- 1
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. https://app.cochat.ai/papers/10.1097/01.sla.0000254367.15810.38
- The paper
- Reynolds, J. V., Muldoon, C., Hollywood, D., Ravi, N., Rowley, S., O’Byrne, K., Kennedy, J., & Murphy, T. J. (2007). Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery. https://doi.org/10.1097/01.sla.0000254367.15810.38
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.